VALN

Valneva SE Form 6-K Summary: Six Months Ended June 30, 2026

Business Context and Reporting Period

This Form 6-K reports the unaudited interim condensed consolidated financial statements for Valneva SE for the six months ended June 30, 2026. Valneva is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases. As of June 30, 2026, the Company employed approximately 620 people globally. The reporting period covers significant operational shifts, including the wind-down of third-party distribution, restructuring initiatives, and updates on key pipeline assets.

Key Financial Metrics

Liquidity and Debt: Cash and cash equivalents stood at €121.5 million as of June 30, 2026. Total borrowings were €184.1 million, primarily consisting of a €180.1 million facility with Pharmakon Advisors (replacing the previous D&O loan). The Company reported a net cash outflow from operating activities of €13.7 million, offset by €24.5 million in net cash generated from financing activities, largely due to a capital raise.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 32.5% (€31.7 million) year-over-year. This was driven by the planned discontinuation of third-party product sales (down 91.6%), distributor transitions in Germany, and the absence of non-recurring outbreak-related sales recorded in H1 2025.
• Gross Margin Compression: Gross profit collapsed from €50.4 million to €6.3 million. The decline was primarily due to lower sales volumes, idle manufacturing costs, and significant one-time charges related to IXCHIQ, including €9.7 million in manufacturing contract cancellation fees and a €4.5 million inventory impairment.
• IXCHIQ Impact: The chikungunya vaccine IXCHIQ contributed significantly to the operating loss (approx. 50% of the total operating loss). Sales dropped to €4.4 million from €7.5 million following the voluntary withdrawal of the U.S. BLA in January 2026 after the FDA suspended the license in August 2025 due to safety concerns.
• Cost Reductions: Operating expenses were managed through a restructuring program announced in May 2026, targeting a 10-15% global workforce reduction. R&D expenses decreased to €30.2 million, and marketing expenses fell to €13.5 million.

Guidance, Outlook, and Risks

Operational Outlook: For the second half of 2026, Valneva plans to focus on Pfizer's submission of marketing applications for the Lyme disease vaccine candidate (LB6V), reporting Phase 2 data for the Shigella vaccine (S4V2), and advancing the commercialization of IXIARO and DUKORAL. The Company expects the restructuring program to generate positive P&L and cash flow impacts in H2 2026.

Capital Raise: In April 2026, Valneva completed a reserved offering raising €37 million immediately, with potential for up to €47 million more if warrants are exercised. Proceeds are designated for pipeline advancement and working capital.

Risk Factors:

• IXCHIQ Safety and Regulatory: Continued risk of license suspension or withdrawal in other markets due to safety signals in elderly populations. The U.S. license withdrawal has already impacted sales and inventory valuation.
• Lyme Vaccine (LB6V): While Phase 3 data showed >70% efficacy, the primary statistical endpoint was not met due to fewer cases than anticipated. Regulatory approval is not guaranteed, and commercialization depends on Pfizer's discretion.
• Liquidity: The business remains capital-intensive. While the Pharmakon loan extends maturity to 2030, the Company may need to raise additional capital to fund operations and pipeline development.
• Manufacturing: The FDA issued Form 483 letters regarding facilities in Livingston and Vienna. Remediation is ongoing, and supply constraints could impact sales.

Investor Verification Checklist

• IXCHIQ Regulatory Status: Verify the current status of IXCHIQ licenses in Europe, Canada, and Brazil, and monitor for any further regulatory actions regarding safety.
• Lyme Vaccine (LB6V) Pathway: Confirm Pfizer's timeline for regulatory submissions and the likelihood of approval given the missed primary statistical endpoint in the VALOR trial.
• Cash Runway: Assess whether the €121.5 million cash balance and the €37 million capital raise are sufficient to fund operations through the next 12-18 months given the elevated burn rate.
• Restructuring Execution: Monitor the implementation of the 10-15% workforce reduction and the associated cost savings in H2 2026.
• Manufacturing Compliance: Track the resolution of FDA Form 483 observations at the Livingston and Vienna sites to ensure uninterrupted supply of IXIARO and IXCHIQ.